Chongqing Sansheng Industrial Co Ltd

Chart & Performance

D1W1MN

P/E

—

P/S

0.90

EPS

—

Div Yield, %

0.00%

Shrs. gr., 5y

-0.07%

Rev. gr., 5y

-6.66%

Revenues

2.03b

-2.25%

Net income

-452m

CFO

-52m

Dividend

Jul 01, 20200.04 CNY/sh

Earnings

Jun 06, 2025

Profile

Chongqing Sansheng Industrial Co.,Ltd. engages in the research and development, production, and sale of building materials and chemicals in China. The company offers commercial concrete, water reducing agents, and expansion agents for industrial and civil buildings, highways, railways, bridges, tunnels, airports, water conservancy and hydropower, etc.; and sulfuric acid for the production of chemical fertilizers, chemical, light industry, textile, steel, water reducer, and other non-fertilizer acid enterprises. It also provides pharmaceutical products comprising intermediates, such as procaine hydrochloride, cefoxitin intermediate, chloramphenicol intermediate, aztreonam intermediate, orlistat intermediate, etc., which are used in antibiotic drugs, anti-hepatitis C drugs, diabetes medicines, benzathine penicillin and cefoxitin, procaine penicillin, and cosmetics; API products, including acetaminophen, cloperidine hydrochloride, levofloxacin mesylate, benoate, procaine hydrochloride, diphenhydramine hydrochloride, etc.; and preparation products, such as compound paracetamol diphenhydramine, cloperidine hydrochloride, clarithromycin sustained-release, diclofenac sodium enteric-coated, acetaminophen, famotidine tablets, etc., which are used in antipyretic and analgesic, antiviral, antibacterial, cough, allergy, local anesthesia, etc., as well as famotidine, diclofenac sodium, nifedipine, acetaminophen, furosemide, and norfloxacin drugs for clinical needs. The company was formerly known as Chongqing Sansheng Special Building Materials Co., Ltd. and changed its name to Chongqing Sansheng Industrial Co.,Ltd. in October 2016. The company was founded in 2002 and is based in Chongqing, China.

URL

http://www.cqssgf.com/

IPO date

Feb 17, 2015

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title CNY in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title CNY in thousands, except ratios and share amounts	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12	2015‑12	2014‑12
Income
Revenues	2,030,233 -2.25%	2,077,024 -16.56%	2,489,145 -2.37%
Cost of revenue	1,799,873	1,886,431	2,245,179
Unusual Expense (Income)
NOPBT	230,360	190,593	243,966
NOPBT Margin	11.35%	9.18%	9.80%
Operating Taxes	81,370	51,259	18,283
Tax Rate	35.32%	26.89%	7.49%
NOPAT	148,990	139,334	225,683
Net income	(452,047)
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current	996,661	1,109,571	801,305
Long-term debt	59,648	40,998	325,330
Deferred revenue		65,290	67,547
Other long-term liabilities	76,386	59,155	57,330
Net debt	964,798	1,032,778	925,716
Cash flow
Cash from operating activities	(51,595)	49,115	139,838
CAPEX
Cash from investing activities	(50,075)	31,041
Cash from financing activities	70,688
FCF	464,592	238,039	582,184
Balance
Cash	91,461	117,741	180,026
Long term investments	50	50	20,893
Excess cash		13,940	76,462
Stockholders' equity	443,419	872,334	1,193,303
Invested Capital	1,739,321	2,129,227	2,380,462
ROIC	7.70%	6.18%	8.88%
ROCE	13.24%	8.89%	9.93%
EV
Common stock shares outstanding	430,521	432,000	432,000
Price	3.38 -25.55%	4.54 -38.48%	7.38 13.71%
Market cap	1,455,160 -25.81%	1,961,280 -38.48%	3,188,160 13.71%
EV	2,632,430	3,317,779	4,440,509
EBITDA	362,498	322,738	393,197
EV/EBITDA	7.26	10.28	11.29
Interest	169,219	157,581	161,027
Interest/NOPBT	73.46%	82.68%	66.00%